Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 779 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gram Positive Bacterial Infection Clear all
Completed Not applicable Interventional

Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy

NCT00000883
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
51
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 26, 2026, 4:22 PM EDT
Terminated No phase listed Observational

A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil

NCT06715254
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 26, 2026, 4:22 PM EDT
Completed No phase listed Observational

Gene Expression in HIV and Tuberculosis Co-infection

NCT01611402
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 26, 2026, 4:22 PM EDT
Completed No phase listed Observational

Healthcare-associated Links in Transmission of Nontuberculous Mycobacteria in Cystic Fibrosis

NCT04024423
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterium Infection
Interventions
Epidemiologic investigation
Other
Lead sponsor
National Jewish Health
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice

NCT01979588
View directory record Official record
Conditions
Influenza Like Illness, Asthma, Group A Streptococcal Infection, Pertussis
Interventions
What's Going Around tool, Control
Other
Lead sponsor
Endeavor Health
Other
Eligibility
Not listed
Enrollment
206,703 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

NCT04775953
View directory record Official record
Conditions
Staphylococcal Bacteraemia
Interventions
Cefazolin, Dalbavancin, Daptomycin, Nafcillin, Oxacillin, Vancomycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age

NCT00467519
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis), DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
1,045 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
42
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)

NCT03950622
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13®
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
14
States / cities
Mesa, Arizona • San Diego, California • Hialeah, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 26, 2026, 4:22 PM EDT
Recruiting Phase 2Phase 3 Interventional

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

NCT03474029
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks, Rifampin daily for 16 weeks
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
Not listed
Enrollment
3,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
7
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Manhattan, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

NCT02288481
View directory record Official record
Conditions
Tuberculosis
Interventions
TBA-354, Placebo
Drug · Other
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS

NCT04258995
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
20 Years to 51 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
4
States / cities
Stockbridge, Georgia • Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 26, 2026, 4:22 PM EDT
Recruiting Phase 2 Interventional

Stool Transplants to Treat Refractory Clostridium Difficile Colitis

NCT02127398
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
fecal microbiota
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

NCT01214993
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions
GSK1349572, Placebo, Iohexol Injection, Para-aminohippurate infusion
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 26, 2026, 4:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET

NCT05609552
View directory record Official record
Conditions
Tuberculosis
Interventions
18F-Pretomanid PET/CT
Combination Product
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

NCT00546572
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13 valent Pneumococcal Conjugate Vaccine, 23vPS
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
70 Years and older
Enrollment
938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
51
States / cities
Mobile, Alabama • Mesa, Arizona • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

NCT05393037
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
V116, Placebo, PCV15, PPSV23, PCV15 - Part B
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

NCT03512288
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, 13vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
39
States / cities
Fayetteville, Arkansas • Downey, California • Huntington Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

NCT06469151
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5148, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Anniston, Alabama • Glendale, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Not applicable Interventional

Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

NCT00113191
View directory record Official record
Conditions
Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
Interventions
Veronate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
3 Days to 5 Days
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 71 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 2 Interventional

Interferon Gamma for Drug Resistant Tuberculosis

NCT00001407
View directory record Official record
Conditions
Pneumonia, Pulmonary Tuberculosis
Interventions
Interferon Gamma
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 4:22 PM EDT
Recruiting Phase 2 Interventional

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

NCT07021794
View directory record Official record
Conditions
Post-COVID / Long-COVID
Interventions
Placebo, Sipavibart
Drug · Biological
Lead sponsor
Nancy Klimas
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

NCT01364571
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, Blood sample, SA4Ag vaccine high dose, Placebo
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
16
States / cities
Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 26, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

NCT00323557
View directory record Official record
Conditions
Leukemia
Interventions
Sargramostim (GM-CSF), Pneumococcal Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 26, 2026, 4:22 PM EDT
Completed No phase listed Observational

Clinical Priority Program-Bone Infection Registry

NCT01677000
View directory record Official record
Conditions
Bone Infection, Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
AO Clinical Investigation and Publishing Documentation
Other
Eligibility
18 Years to 130 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Columbia, Missouri • Rochester, New York • Danville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 26, 2026, 4:22 PM EDT